KPV peptide.
Three amino acids. Real biology.
KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone — Lys-Pro-Val, a sequence so short it's easy to underestimate, and a molecule with unusually well-characterized anti-inflammatory activity in the gut and skin. This reference covers the published mechanism, the clinical evidence base, the dosing protocols used in research settings, and the April 2026 regulatory picture that shifted KPV's compounding status.
What KPV actually is
KPV is a three-amino-acid peptide — lysine, proline, valine — corresponding to positions 11 through 13 of α-melanocyte-stimulating hormone. The parent hormone α-MSH is a 13-residue peptide with a long list of biological activities including pigmentation, appetite regulation, and anti-inflammatory signaling. In the 1990s, researchers including the Lipton lab demonstrated that KPV retains the anti-inflammatory activity of the parent molecule without the pigmentation or melanocortin-receptor-driven effects. That makes it useful as a research tool and a candidate for therapeutic use in inflammatory conditions — particularly in the gut, where its small size and peptidase resistance let it survive oral administration better than most peptides.
KPV coverage organized by topic
Mechanism of action and the α-MSH research heritage. Published clinical evidence for gut inflammation and autoimmune applications. Dosing protocols used in research, including oral, injectable, and topical routes. Safety profile. And the specific comparison to BPC-157 that users asking about KPV frequently want to understand.
KPV peptide benefits and mechanism
The α-MSH research heritage, NF-κB inhibition, melanocortin-independent action, and the conditions where KPV has published evidence.
Read page → 02 / 05KPV side effects and safety
Published side effect data across administration routes, contraindications, drug interactions, and the 2026 regulatory status.
Read page → 03 / 05KPV for gut health
Evidence for IBD, ulcerative colitis, Crohn's disease, leaky gut, and IBS; dosing considerations; honest framing on current clinical data.
Read page → 04 / 05KPV dosage and protocols
Oral dosing, subcutaneous injection protocols, topical application, cycling, and practical administration considerations.
Read page → 05 / 05KPV vs BPC-157
Mechanism differences, indication-by-indication comparison, safety profiles, and practical guidance on which peptide fits which goal.
Read page →KPV at a glance
| Fact | Detail |
|---|---|
| Amino acid sequence | Lysine-Proline-Valine (Lys-Pro-Val or K-P-V in single-letter code). Derived from α-MSH positions 11-13. |
| Molecular weight | Approximately 342 g/mol. Small enough to survive oral passage intact in many formulations — a significant advantage over most bioactive peptides. |
| Research heritage | Characterized extensively by the Lipton lab and collaborators throughout the 1990s and 2000s. Anti-inflammatory activity independent of melanocortin receptor signaling has been documented across multiple published studies. |
| Primary applications | Inflammatory bowel conditions (IBD, ulcerative colitis, Crohn's disease, IBS) via oral administration. Inflammatory skin conditions (psoriasis, eczema, rosacea) via topical application. Systemic anti-inflammatory effects via injection. |
| Regulatory status (April 2026) | KPV was removed from FDA Category 2 bulk drug substances list on April 15, 2026, after the nomination was withdrawn. FDA announced intention to consult the Pharmacy Compounding Advisory Committee on July 23, 2026 regarding potential inclusion of KPV acetate and KPV (free base) on the 503A bulks list. Status pending PCAC review. |